Skip to main content

Main menu

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
  • Other Publications
    • www.clevelandclinic.org

User menu

  • Register
  • Log in

Search

  • Advanced search
Cleveland Clinic Journal of Medicine
  • Other Publications
    • www.clevelandclinic.org
  • Register
  • Log in
Cleveland Clinic Journal of Medicine

Advanced Search

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
1-Minute Consult

What is the hepatitis B vaccination regimen in chronic kidney disease?

Kheng Yong Ong, BSc (Pharm) (Hons), Hong Yun Wong, BSc (Pharm) (Hons) and Giat Yeng Khee, PharmD
Cleveland Clinic Journal of Medicine January 2018, 85 (1) 32-34; DOI: https://doi.org/10.3949/ccjm.85a.17017
Kheng Yong Ong
Pharmacist, Department of Pharmacy, Singapore General Hospital, Singapore
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: [email protected]
Hong Yun Wong
Pharmacist, Department of Pharmacy, Khoo Teck Puat Hospital, Singapore
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Giat Yeng Khee
Senior Clinical Pharmacist. Department of Pharmacy, Singapore General Hospital, Singapore
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

For patients age 16 and older with advanced chronic kidney disease (CKD), including those undergoing hemodialysis, we recommend a higher dose of hepatitis B virus (HBV) vaccine, more doses, or both. Vaccination with a higher dose may improve the immune response. The hepatitis B surface antibody (anti-HBs) titer should be monitored 1 to 2 months after completion of the vaccination schedule and annually thereafter, with a target titer of 10 IU/mL or greater. For patients who do not develop a protective antibody titer after completing the initial vaccination schedule, the vaccination schedule should be repeated.

RECOMMENDED DOSES AND SCHEDULES

Recommendation 1

Give higher vaccine doses, increase the number of doses, or both.

Rationale. Patients with CKD, especially those on hemodialysis, are in an immunocompromised state and thus are less likely to achieve protective anti-HBs levels after vaccination with standard dosages.1–3 Two main vaccine formulations are available (Table 1). Recombivax-HB contains 40 μg/mL and is given in a 3-dose schedule at 0, 1, and 6 months. Engerix-B contains a standard dose of 20 μg/mL and should be given in a 4-dose schedule at double the standard dose (ie, a total of 40 μg/mL). Both regimens are recommended in the 2017 update of the United States Advisory Committee on Immunization Practices (ACIP) recommendations for adult immunization schedule.4

View this table:
  • View inline
  • View popup
TABLE 1

Recommended vaccination regimens for hepatitis B virus in chronic kidney disease

Recommendation 2

A 4-dose regimen may provide a better antibody response than a 3-dose regimen. (Note: This recommendation applies only to Engerix-B; 4 doses of Recombivax-HB would be an off-label use.)

Rationale. The US Centers for Disease Control and Prevention reported that after completion of a 3-dose vaccination schedule, the median proportion of patients developing a protective antibody response was 64% (range 34%–88%) vs a median of 86% (range 40%–98%) after a 4-dose schedule.3

Lacson et al5 compared antibody response rates after 3 doses of Recombivax-HB and after 4 doses of Engerix-B and found a better response rate with the 4-dose schedule. The rate of persistent protective anti-HBs titer after 1 year was 77% for Engerix-B vs 53% for Recombivax-HB.

Agarwal et al6 evaluated response rates in patients who had mild CKD (serum creatinine levels 1.5–3.0 mg/dL), moderate CKD (creatinine 3.0–6.0 mg/dL), and severe CKD (creatinine > 6.0 mg/dL). The seroconver-sion rates after 3 doses of 40-μg HBV vaccine were 87.5% in those with mild CKD, 66.6% in those with moderate CKD, and 35.7% in those with severe disease. After a fourth dose, rates improved significantly to 100%, 77%, and 36.4%, respectively.

Recommendation 3

In patients with CKD, vaccination should be done early, before they become dependent on hemodialysis.

Rationale. Patients with advanced CKD may have a lower seroconversion rate. Fraser et al7 found that after a 4-dose series, the seroprotection rate in adult prehemodialysis patients with serum creatinine levels of 4 mg/dL or less was 86%, compared with 37% in patients with serum creatinine levels above 4 mg/dL, of whom 88% were on hemodialysis.7

In a 2003 prospective cohort study by DaRoza et al,8 patients with higher levels of kidney function were more likely to respond to HBV vaccination, and the level of kidney function was found to be an independent predictor of seroconversion.8

A 2012 prospective study by Ghadiani et al9 compared seroconversion rates in patients with stage 3 or 4 CKD vs patients on hemodialysis, with medical staff as controls. The authors reported seroprotection rates of 26.1% in patients on hemodialysis, 55.2% in patients with stage 3 or 4 CKD, and 96.2% in controls. They concluded that vaccination is more likely to induce seroconversion in earlier stages of kidney disease.9

MONITORING THE RESPONSE TO VACCINATION AND REVACCINATION

Testing after vaccination is recommended to determine response. Testing should be done 1 to 2 months after the last dose of the vaccination schedule.1–3 Anti-HBs levels 10 IU/mL and greater are considered protective.10

Revaccination with a full vaccination series is recommended for patients who do not develop adequate levels of protective antibodies after completion of the vaccination schedule.2 Reported response rates to revaccination have varied from 40% to 50% after 2 or 3 additional intramuscular doses of 40 μg, to 64% after 4 additional intramuscular doses of 10 μg.3 Serologic testing should be repeated after the last dose of the vaccination series, as serologic testing after only 1 or 2 additional doses appears to be no more cost-effective.2,3

To the best of our knowledge, no data exist to indicate that in nonresponders, further doses given

ANTIBODY PERSISTENCE AND BOOSTER DOSES

Antibody levels fall with time in patients on hemodialysis. Limited data suggest that in patients who respond to the primary vaccination series, antibodies remain detectable for 6 months in 80% to 100% (median 100%) of patients and for 12 months in 58% to 100% (median 70%) of patients.3 The need for booster doses should be assessed by annual monitoring.2,11 Booster doses should be given when the anti-HBs titer declines to below 10 IU/mL. Limited data indicate that nearly all such patients would respond to a booster dose.3

OTHER WAYS TO IMPROVE VACCINE RESPONSE

Other strategies to improve vaccine response, such as the addition of adjuvants or immunostimulants, have shown variable success.12 Intradermal HBV vaccination in patients on chronic hemodialysis has also been proposed. The efficacy of intradermal vaccination may be related to the dense network of immunologic dendritic cells within the dermis. After intradermal administration, the antigen is taken up by dendritic cells residing in the dermis, which mature and travel to the regional lymph node where further immunostimulation takes place.13

In a systematic review of four prospective trials with a total of 204 hemodialysis patients,13 a significantly higher proportion of patients achieved seroconversion with intradermal HBV vaccine administration than with intramuscular administration. The authors concluded that the intradermal route in primary nonresponders undergoing hemodialysis provides an effective alternative to the intramuscular route to protect against HBV infection in this highly susceptible population.

Additional well-designed, double-blinded, randomized trials are needed to establish clear guidelines on intradermal HBV vaccine dosing and vaccination schedules.

  • Copyright © 2018 The Cleveland Clinic Foundation. All Rights Reserved.

REFERENCES

  1. ↵
    1. Grzegorzewska AE
    . Hepatitis B vaccination in chronic kidney disease: review of evidence in non-dialyzed patients. Hepat Mon 2012; 12:e7359.
    OpenUrl
  2. ↵
    1. Chi C,
    2. Patel P,
    3. Pilishvili T,
    4. Moore M,
    5. Murphy T,
    6. Strikas R
    . Guidelines for vaccinating kidney dialysis patients and patients with chronic kidney disease. www.cdc.gov/dialysis/PDFs/Vaccinating_Dialysis_Patients_and_Patients_dec2012.pdf. Accessed September 6, 2017.
  3. ↵
    Recommendations for preventing transmission of infections among chronic hemodialysis patients. MMWR Recomm Rep 2001; 50:1–43.
    OpenUrlPubMed
  4. ↵
    1. Kim DK,
    2. Riley LE,
    3. Harriman KH,
    4. Hunter P,
    5. Bridges CB; Advisory Committee on Immunization Practices
    . Recommended immunization schedule for adults aged 19 years or older, United States, 2017. Ann Intern Med 2017; 166:209–219.
    OpenUrl
  5. ↵
    1. Lacson E,
    2. Teng M,
    3. Ong J,
    4. Vienneau L,
    5. Ofsthun N,
    6. Lazarus JM
    . Antibody response to Engerix-B and Recombivax-HB hepatitis B vaccination in end-stage renal disease. Hemo-dialysis international. Hemodial Int 2005; 9:367–375.
    OpenUrlCrossRefPubMed
  6. ↵
    1. Agarwal SK,
    2. Irshad M,
    3. Dash SC
    . Comparison of two schedules of hepatitis B vaccination in patients with mild, moderate and severe renal failure. J Assoc Physicians India 1999; 47:183–185.
    OpenUrlPubMed
  7. ↵
    1. Fraser GM,
    2. Ochana N,
    3. Fenyves D, et al
    . Increasing serum creatinine and age reduce the response to hepatitis B vaccine in renal failure patients. J Hepatol 1994; 21:450–454.
    OpenUrlCrossRefPubMed
  8. ↵
    1. DaRoza G,
    2. Loewen A,
    3. Djurdjev O, et al
    . Stage of chronic kidney disease predicts seroconversion after hepatitis B immunization: earlier is better. Am J Kidney Dis 2003; 42:1184–1192.
    OpenUrlCrossRefPubMed
  9. ↵
    1. Ghadiani MH,
    2. Besharati S,
    3. Mousavinasab N,
    4. Jalalzadeh M
    . Response rates to HB vaccine in CKD stages 3-4 and hemodialysis patients. J Res Med Sci 2012; 17:527–533.
    OpenUrl
  10. ↵
    1. Jack AD,
    2. Hall AJ,
    3. Maine N,
    4. Mendy M,
    5. Whittle HC
    . What level of hepatitis B antibody is protective? J Infect Dis 1999; 179:489–492.
    OpenUrlCrossRefPubMed
  11. ↵
    Guidelines for vaccination in patients with chronic kidney disease. Indian J Nephrol 2016; 26(suppl 1):S15–S18.
    OpenUrl
  12. ↵
    1. Somi MH,
    2. Hajipour B
    . Improving hepatitis B vaccine efficacy in end-stage renal diseases patients and role of adjuvants. ISRN Gastroenterol 2012; 2012:960413.
    OpenUrlPubMed
  13. ↵
    1. Yousaf F,
    2. Gandham S,
    3. Galler M,
    4. Spinowitz B,
    5. Chary-tan C
    . Systematic review of the efficacy and safety of intradermal versus intramuscular hepatitis B vaccination in end-stage renal disease population unresponsive to primary vaccination series. Ren Fail 2015; 37:1080–1088.
    OpenUrl
PreviousNext
Back to top

In this issue

Cleveland Clinic Journal of Medicine: 85 (1)
Cleveland Clinic Journal of Medicine
Vol. 85, Issue 1
1 Jan 2018
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Cleveland Clinic Journal of Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
What is the hepatitis B vaccination regimen in chronic kidney disease?
(Your Name) has sent you a message from Cleveland Clinic Journal of Medicine
(Your Name) thought you would like to see the Cleveland Clinic Journal of Medicine web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
What is the hepatitis B vaccination regimen in chronic kidney disease?
Kheng Yong Ong, Hong Yun Wong, Giat Yeng Khee
Cleveland Clinic Journal of Medicine Jan 2018, 85 (1) 32-34; DOI: 10.3949/ccjm.85a.17017

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
What is the hepatitis B vaccination regimen in chronic kidney disease?
Kheng Yong Ong, Hong Yun Wong, Giat Yeng Khee
Cleveland Clinic Journal of Medicine Jan 2018, 85 (1) 32-34; DOI: 10.3949/ccjm.85a.17017
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Linkedin Share Button

Jump to section

  • Article
    • RECOMMENDED DOSES AND SCHEDULES
    • MONITORING THE RESPONSE TO VACCINATION AND REVACCINATION
    • ANTIBODY PERSISTENCE AND BOOSTER DOSES
    • OTHER WAYS TO IMPROVE VACCINE RESPONSE
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • What diagnostic tests should be done after discovering clubbing in a patient without cardiopulmonary symptoms?
  • Does my adult patient need a measles vaccine?
  • Do I need to treat supine hypertension in my hospitalized patient?
Show more 1-Minute Consult

Similar Articles

Subjects

  • Hepatology
  • Infectious Diseases
  • Nephrology
  • Preventive Care

Navigate

  • Current Issue
  • Past Issues
  • Supplements
  • Article Type
  • Specialty
  • CME/MOC Articles
  • CME/MOC Calendar
  • Media Kit

Authors & Reviewers

  • Manuscript Submission
  • Authors & Reviewers
  • Subscriptions
  • About CCJM
  • Contact Us
  • Cleveland Clinic Center for Continuing Education
  • Consult QD

Share your suggestions!

Copyright © 2025 The Cleveland Clinic Foundation. All rights reserved. The information provided is for educational purposes only. Use of this website is subject to the website terms of use and privacy policy. 

Powered by HighWire